相关实验视频
Updated: Jan 11, 2026

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.2K
胆固醇和心血管事件:公布的随机对照试验的更新元分析
Sining Xie1, Federica Galimberti2, Elena Olmastroni1,2
1Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Journal of internal medicine
|November 14, 2025
概括
低剂量胆固醇可显著降低主要不良心血管事件 (MACE) 和相关结果,如心肌梗塞和中风在二次预防中. 这一元分析证实了其在标准护理下使用超过12个月时的有效性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 科尔奇辛的降低心血管风险潜力仍在争论中.
- 最近的一项研究质疑了其既定的益处.
- 本次元分析解决了二次预防中的不确定性.
研究的目的:
- 评估菌素对心血管结果的影响.
- 评估其在二次心血管预防中的作用.
- 综合来自随机对照试验 (RCT) 的证据.
主要方法:
- 在2025年3月之前对主要数据库进行系统搜索.
- 包括RCT比较胆固醇与安慰剂的时间≥12个月.
- 使用固定和随机效应模型进行主要心血管不良事件 (MACE) 的元分析.
主要成果:
- 分析了6个RCT,其中包括21,774名患者.
- 科尔奇辛显著降低了MACEs (RR 0.74 [0.60-0.92]). 这种药物可以减少MACEs.
- 在心肌梗塞 (RR 0.85 [0.73-0.98]) 和中风 (RR 0.79 [0.65-0.95]) 中观察到显著的减少.
- 没有对心脏死亡或心脏再血管化的显著影响.
结论:
- 低剂量的胆固醇可以有效地减少MACEs.
- 结果支持其作为标准护理的附加疗法.
- 建议治疗时间至少为12个月.
相关概念视频
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Rheumatic Heart Disease III: Medical Management
272
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
272
Coronary Artery Disease V: Interprofessional Care
207
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
207
Coronary Artery Disease IV: Preventive Measures
578
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
578
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K

